Alexis Ogdie comments on the results of two phase 3 trials demonstrating the potential of upadacitinib as a treatment option for psoriatic arthritis patients with and without prior exposure to biologic agents (3:59).
09-06-2020 | EULAR 2020 | Conference coverage | Video